How mRNA Technology is Revolutionising Medicine Beyond Vaccines

Info

mRNA technology, initially acknowledged for its pivotal role in the development of COVID-19 vaccines, is now expanding its impact in the field of medicine beyond just infectious diseases.

In contrast to conventional therapies, mRNA serves as a messenger that instructs cells to generate specific proteins, initiating a therapeutic response. This innovative platform has paved the way for numerous applications, including personalized cancer therapies, genetic disorder treatments, and solutions for autoimmune diseases.

Dr. Daniel Getts, the CEO of Myeloid Therapeutics, has been appointed by the NSW Government to lead the new RNA Research and Pilot Manufacturing Facility, which is currently being constructed at Macquarie University.

In his discussion, Daniel will outline the advancements in RNA technology and how it is transforming approaches to treating various diseases, promising more precise, effective, and flexible medical solutions.

The session will highlight how the full potential of mRNA is just beginning to unfold, heralding a new chapter in therapeutic innovation.

About the Speaker

Dr. Daniel Getts
CEO, Myeloid Therapeutics

Daniel is a prominent expert in creating new treatments for cancer and autoimmune conditions. As an immunologist educated at the University of Sydney, he co-founded Myeloid Therapeutics, recognized globally for its RNA therapeutic advancements.

This year, he also established Aurora Biosynthetics Pty Ltd in collaboration with the NSW Government, aimed at boosting DNA and RNA production within the evolving RNA ecosystem in Sydney. Aurora Biosynthetics will oversee the $96 million RNA Research and Pilot Manufacturing Facility, which is under development at Macquarie University’s Wallumattagal Campus.

Daniel has successfully attracted over US$1 billion in private investment, leading to the discovery and implementation of nine groundbreaking therapeutics.

Moreover, he was a co-founder of Cour Pharmaceuticals, contributing to the creation of TIMP-GLIA, a nanotherapy aimed at inducing gluten tolerance.

With more than 50 peer-reviewed publications and over 100 patents, Daniel has made noteworthy contributions to the fields of immunology, cancer treatment, and RNA-based therapies.